No Data
Funds are being frantically invested, and pharmaceutical stocks are back in the spotlight! Bullish policies and fundamentals have arrived.
Performance is steadily increasing.
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
Is Obio Technology (Shanghai) (SHSE:688238) Using Debt In A Risky Way?
He Yuan Bio (688238.SH): A total of 1.0023 company shares have been repurchased.
On March 24, Gelonghui reported that Heyuan Biological (688238.SH) announced that as of March 21, 2025, the company had repurchased a total of 6.505 million shares through the trading system of the Shanghai Exchange using a centralized bidding method, accounting for 1.0023% of the total shares, which is an increase of 0.8297% compared to the last disclosed figure. The highest price for the repurchase transaction was 5.85 yuan/share, the lowest price was 5.34 yuan/share, and the total amount paid was 36.2533 million yuan (excluding stamp duty, trading commissions, and other transaction costs).
Core technical staff Wei Houliang has left He Yuan Biology (688238.SH).
He Yuan Biological (688238.SH) announced that due to personal reasons, Mr. Wei Houliang, the core technical staff, has resigned from the company...
Approximately 0.174 billion restricted shares of He Yuan Biotechnology (688238.SH) will be listed and traded on March 24.
Heyuan Biological (688238.SH) announced that the restricted shares for this listing are part of the company's initial public offering...
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?
